Promising prostate cancer treatment trial halted early

NCT ID NCT04876651

Terminated Disease control Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 study tested a radioactive antibody called 177Lu-DOTA-rosopatamab combined with standard care for men with metastatic castration-resistant prostate cancer that had progressed after hormone therapy. The goal was to see if the combination slowed cancer growth or improved survival. However, the trial was terminated early and only enrolled 16 participants, so the findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 177Lu-DOTA-rosopatamab (a radioactive antibody targeting prostate cancer cells)
What this could lead to: If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to hormone therapy.
What could go wrong: The trial was terminated early with only 16 participants, so results are very limited. It is unclear if the treatment is safe or effective, and it may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Locations

'GenesisCare Murdoch'

Murdoch, Western Australia, 6150, Australia
Auckland City Hospital

Auckland, 1023, New Zealand
Austin Health

Melbourne, Victoria, 3083, Australia
Monash Health

Clayton, Victoria, 3168, Australia
Princess Alexandra Hospital

Woolloongabba, Queensland, 4102, Australia
Westmead Hospital

Westmead, New South Wales, 2145, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.